C2C Stock Chart & Stats
€6.25
€0.00(0.00%)
At close: 4:00 PM EST
€6.25
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.05 - €6.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.44M
Enterprise Value€3.34B
Total Cash (Recent Filing)€297.79M
Total Debt (Recent Filing)€3.63B
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,815,458
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00853
P/FCF Ratio-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Growth TrendA clear top-line recovery (25.9% YoY in 2025) indicates rising patient volumes and better utilization across the group. Durable revenue momentum supports fixed-cost absorption, gives management room to improve margins, and underpins medium-term recovery prospects if sustained by operations.
Large Asset Base And Partial DeleveragingA sizable asset base provides collateral and operational scale, improving options for refinancing or asset optimization. The year-over-year reduction in total debt shows initial deleveraging momentum, which, if continued, can materially improve leverage metrics and financing flexibility over the next several quarters.
Access To External Capital Through Hong Kong SubsidiaryThe subsidiary's successful convertible bond placement and H‑share market presence expand the group’s financing toolkit. Access to Hong Kong capital markets and convertible instruments provides durable funding flexibility, potential equity conversion alleviating parent leverage, and an avenue to fund growth or stabilize operations.
Bears Say
Chronic Negative Operating And Free Cash FlowPersistent operating and free cash flow deficits force reliance on external financing and constrain reinvestment. Ongoing cash burn increases refinancing needs, elevates liquidity and covenant risk, and limits the company's ability to self-fund growth or manage downturns over the medium term.
Highly Leveraged Balance Sheet With Negative EquitySubstantial debt and negative equity materially limit financial flexibility and increase refinancing risk. The imbalanced capital structure raises the probability of stakeholder dilution, higher financing costs, and constrained strategic choices, impairing the company’s resilience to shocks over the next several quarters.
Recurring Operating And Net Losses; Volatile Gross ProfitSustained operating and net losses, plus volatile or negative gross profit, point to structural pricing, cost, or mix issues in core services. Without durable margin recovery, the business risks prolonged unprofitability, weakening cash flow generation and making long-term value creation dependent on material operational change.
Concord Medical Services News
C2C FAQ
What was Concord Medical Services’s price range in the past 12 months?
Concord Medical Services lowest stock price was €6.05 and its highest was €6.25 in the past 12 months.
What is Concord Medical Services’s market cap?
Concord Medical Services’s market cap is €17.44M.
When is Concord Medical Services’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Concord Medical Services’s earnings last quarter?
Currently, no data Available
Is Concord Medical Services overvalued?
According to Wall Street analysts Concord Medical Services’s price is currently Overvalued.
Does Concord Medical Services pay dividends?
Concord Medical Services does not currently pay dividends.
What is Concord Medical Services’s EPS estimate?
Concord Medical Services’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Medical Services have?
Concord Medical Services has 2,815,458 shares outstanding.
What happened to Concord Medical Services’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Concord Medical Services?
Currently, no hedge funds are holding shares in DE:C2C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Medical Services
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Technical Analysis
American Shared Hospital Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―